MoonLake Immunotherapeutics's total assets for Q2 2024 were $544.88M, a decrease of -3.41% from the previous quarter. MLTX total liabilities were $14.85M for the fiscal quarter, a 26.56% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.